Tue, 26 Jan 2010 13:11:01 -0500 PVI, PeerView Institute for Medical Education http://www.peerviewpress.com Podcast Maker v1.3.8b - http://www.lemonzdream.com/podcastmaker Thought leader perspectives on current clinical advances in medicine PeerView Press is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView Press is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes. 2007 PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018 webmaster@peerviewpress.com http://media.peerviewpress.com/000136/podcast/pvi/xml/podcast_HematologyCME-CNE-CPE_144.jpg http://www.peerviewpress.com 144 144 Science & Medicine CME, Medical Education, continuing medical education, CME credits, PeerView Press, inSession, inReview, CE, Haematology no PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. http://media.peerviewpress.com/000136/podcast/pvi/mp3/PPVNE05844r77.mp3 Tue, 26 Jan 2010 12:58:24 -0500 Science, Medicine no 00:26:18 follicular lymphoma, NHL, rituximab, CHOP, relapsed, refractory, bendamustine, autologous, allogeneic, HSCT, CD20 PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PPVNE05844CMEinfo.pdf Tue, 26 Jan 2010 12:58:15 -0500 Science, Medicine no 00:00:00 follicular lymphoma, NHL, rituximab, CHOP, relapsed, refractory, bendamustine, autologous, allogeneic, HSCT, CD20 PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts provide recommendations for management of disease- and treatment-related complications in multiple myeloma. In the 3 presentations, issues related to thrombosis, neuropathy, and myeloma bone disease are discussed. http://media.peerviewpress.com/000136/podcast/pvi/mp3/PA04348FCr66.mp3 Mon, 21 Sep 2009 15:16:50 -0400 Science, Medicine no 00:27:28 peripheral neuropathy, bortezomib, multiple myeloma, DVT, bone disease, vincristine, VTE, LMWH PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA04348FCCMEinfo.pdf Mon, 21 Sep 2009 15:16:47 -0400 Science, Medicine no 00:00:00 peripheral neuropathy, bortezomib, multiple myeloma, DVT, bone disease, vincristine, VTE, LMWH PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts in CML management discuss the nature of higher risk CML and the current controversies over the criteria that define accelerated-phase and blast-crisis disease. In addition, the faculty will review the currently recommended treatment options for these patient populations and discuss the changed role of tyrosine kinase inhibitor (TKI) therapy in this more advanced setting. http://media.peerviewpress.com/000136/podcast/pvi/mp3/PA05790FCe24.mp3 Mon, 17 Aug 2009 13:42:34 -0400 Science, Medicine no 00:26:18 chronic myeloid leukemia, CML, TKI, targeted therapy, blast, chronic, accelerated, phase, imatinib PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA05790FCCMEinfo.pdf Mon, 17 Aug 2009 13:42:32 -0400 Science, Medicine no 00:00:00 chronic myeloid leukemia, CML, TKI, targeted therapy, blast, chronic, accelerated, phase, imatinib PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, an expert in CLL management discusses the elements of high-risk CLL and the appropriate assessment of poor-prognosis features leading to optimal therapy selection in both the upfront and relapsed/refractory setting. Treatment decisions in unsymptomatic and progressive disease will be explored, and the management of elderly individuals will also be considered. http://media.peerviewpress.com/000136/podcast/pvi/mp3/PA05757FCp155.mp3 Thu, 16 Jul 2009 16:08:03 -0400 Science, Medicine no 00:23:46 high-risk, chronic lymphocytic leukemia, CLL, elderly, relapsed, refractory, upfront, alemtuzumab, fludarabine PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA05757FCCMEinfo.pdf Thu, 16 Jul 2009 16:08:00 -0400 Science, Medicine no 00:00:00 high-risk, chronic lymphocytic leukemia, CLL, elderly, relapsed, refractory, upfront, alemtuzumab, fludarabine PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts discuss the latest advances in the treatment of multiple myeloma, with a focus on appropriate and clinically relevant endpoints for assessing the benefit of new therapies, and results of recent clinical trials to determine if these newer agents have convincingly demonstrated improvements in efficacy. http://media.peerviewpress.com/000136/podcast/pvi/mp3/PA05541FCr440.mp3 Thu, 02 Jul 2009 16:19:13 -0400 Science, Medicine no 00:23:51 multiple myeloma, endpoints, bortezomib, cytogenetics, VAD, ASCT, dexamethasone, lenalidomide. ASH, ASCO PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA05541FCCMEinfo.pdf Thu, 02 Jul 2009 16:19:10 -0400 Science, Medicine no 00:00:00 multiple myeloma, endpoints, bortezomib, cytogenetics, VAD, ASCT, dexamethasone, lenalidomide. ASH, ASCO PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts in management of CKD-related anemia discuss the inflammatory and other mechanisms that affect hemoglobin variability and hyporesponsiveness, as well as strategies to achieve optimal hemoglobin levels. http://podcast.peerviewpress.com/haematology/PPVNE05896FCe031.mp3 http://media.peerviewpress.com/000136/podcast/pvi/mp3/PPVNE05896FCe031.mp3 Fri, 26 Jun 2009 15:22:17 -0400 Science, Medicine no 00:29:30 CKD, chronic kidney disease, anemia, CKD anemia, kidney disease PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PPVNE05896FCCMEinfo.pdf Fri, 26 Jun 2009 15:22:14 -0400 Science, Medicine no 00:00:00 CKD, chronic kidney disease, anemia, CKD anemia, kidney disease PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts in multiple myeloma bone health management discuss the development and clinical impact of myeloma bone disease and the identification of several promising therapeutic targets within the bone microenvironment. Several other topics will be addressed, including the current recommendations for bone disease assessment and management, as well as the potential role of novel therapies with bone protective aspects. http://podcast.peerviewpress.com/haematology/PA05569FCr447.mp3 http://media.peerviewpress.com/000136/podcast/pvi/mp3/PA05569FCr447.mp3 Fri, 22 May 2009 15:48:00 -0400 Science, Medicine no 00:24:11 multiple myeloma bone disease, MBD, bisphosphonates, zoledronic acid, RANK Ligand, ACE, activin PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA05569FCCMEinfo.pdf Fri, 22 May 2009 15:47:57 -0400 Science, Medicine no 00:00:00 multiple myeloma bone disease, MBD, bisphosphonates, zoledronic acid, RANK Ligand, ACE, activin PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, an expert in MCL discusses the characteristics of this relatively rare and clinically challenging disease, including its natural course and typical unresponsiveness to most front-line treatment options. The nature of resistant disease will also be profiled, and the activity of a novel generation of therapeutics in previously treated patients will be evaluated. http://media.peerviewpress.com/000136/podcast/pvi/mp3/PA05230FCn208.mp3 Wed, 13 May 2009 10:17:58 -0400 Science, Medicine no 00:18:52 mantle cell lymphoma, MCL, CVAD, rituximab, everolimus, mTOR, PINNACLE, bortezomib, temsirolimus, ASH PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA05230FCCMEinfo.pdf Wed, 13 May 2009 10:17:56 -0400 Science, Medicine no 00:00:00 mantle cell lymphoma, MCL, CVAD, rituximab, everolimus, mTOR, PINNACLE, bortezomib, temsirolimus, ASH PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts in the management of adults with hemophilia and inhibitors discuss the diagnosis and treatment of allo- and autoantibodies, as well as future directions for managing patients with hemophilia and inhibitors. http://media.peerviewpress.com/000136/podcast/pvi/mp3/PA05327FCe027.mp3 Thu, 30 Apr 2009 14:24:33 -0400 Science, Medicine no 00:54:23 hemophilia, hemophilia inhibitors, hemophilia treatment, alloantibodies, autoantibodies PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA05327FCCMEinfo.pdf Thu, 30 Apr 2009 14:24:29 -0400 Science, Medicine no 00:00:00 hemophilia, hemophilia inhibitors, hemophilia treatment, alloantibodies, autoantibodies PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, an expert in iron overload discusses the differences between hereditary and transfusional hemochromatosis, and evaluates the role of iron chelation in the management of the latter, including both single-agent and combination approaches. New data on the ability of chelators to reduce cardiac iron burden in patients with transfusional iron overload are also discussed. http://media.peerviewpress.com/000136/podcast/pvi/mp3/PA05130FCn202.mp3 Wed, 22 Apr 2009 11:38:43 -0400 Science, Medicine no 00:23:04 hemochramatosis, chelator, iron overload, MDS, transfusion, transferrin, thalassemia, deferiprone, deferoxamine PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA05130FCCMEinfo.pdf Wed, 22 Apr 2009 11:38:40 -0400 Science, Medicine no 00:00:00 hemochramatosis, chelator, iron overload, MDS, transfusion, transferrin, thalassemia, deferiprone, deferoxamine PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Experts in MDS and AML discuss the clinical importance of new findings in these settings, specifically the following topics: an evaluation of modified induction/consolidation chemotherapy in AML, an update on epigenetic treatment and the potential of epigenetic combinations to augment activity in MDS and AML, and the relevance of newer prognostic models to a well-rounded clinical approach. Faculty will also discuss new data on the mechanisms of epigenetic agents, and whether these data possess prognostic or predictive implications. http://media.peerviewpress.com/000136/podcast/pvi/mp3/PA05351FCs514.mp3 Tue, 03 Mar 2009 15:09:44 -0500 Science, Medicine no 00:39:11 MDS, AML, hematologic malignancies, ASH 2008, methylation, HDAC inhibitors, epigenetics PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA05351FCCMEinfo.pdf Tue, 03 Mar 2009 15:09:42 -0500 Science, Medicine no 00:00:00 MDS, AML, hematologic malignancies, ASH 2008, methylation, HDAC inhibitors, epigenetics